Literature DB >> 30353422

P2X7 Receptor Antagonist A804598 Inhibits Inflammation in Brain and Liver in C57BL/6J Mice Exposed to Chronic Ethanol and High Fat Diet.

Daniel Freire1,2, Rachel E Reyes3, Ared Baghram3, Daryl L Davies3, Liana Asatryan4.   

Abstract

Chronic low-grade neuroinflammation is increasingly implicated in organ damage caused by alcohol abuse. Purinergic P2X7 receptors (P2X7Rs) play an important role in the generation of inflammatory responses during a number of CNS pathologies as evidenced from studies using pharmacological inhibition approach. P2X7Rs antagonism has not been tested during chronic alcohol abuse. In the present study, we tested the potential of P2X7R antagonist A804598 to reduce/abolish alcohol-induced neuroinflammation using chronic intragastric ethanol infusion and high-fat diet (Hybrid) in C57BL/6J mice. We have previously demonstrated an increase in neuroinflammatory response in 8 weeks of Hybrid paradigm. In the present study, we found neuroinflammatory response to 4 weeks of Hybrid exposure. A804598 treatment reversed the changes in microglia and astrocytes, reduced/abolished increases in mRNA levels of number of inflammatory markers, including IL-1β, iNOS, CXCR2, and components of inflammatory signaling pathways, such as TLR2, CASP1, NF-kB1 and CREB1, as well in the protein levels of pro-IL-1β and Nf-kB1. The P2X7R antagonist did not affect the increase in mRNA levels of fraktalkine (CX3CL1) and its receptor CX3CR1, an interaction that plays a neuroprotective role in neuron-glia communication. P2X7R antagonism also resulted in reduction of the inflammatory markers but did not alter steatosis in the liver. Taken together, these findings demonstrate how P2X7R antagonism suppresses inflammatory response in brain and liver but does not alter the neuroprotective response caused by Hybrid exposure. Overall, these findings support an important role of P2X7Rs in inflammation in brain and liver caused by combined chronic alcohol and high-fat diet. Graphical Abstract ᅟ.

Entities:  

Keywords:  Immunofluorescence; Intragastric ethanol and high fat diet exposure; Liver inflammation and steatosis; Neuroinflammation; Purinergic P2X7 receptor pharmacological inhibition; Taqman custom gene expression

Mesh:

Substances:

Year:  2018        PMID: 30353422      PMCID: PMC6494709          DOI: 10.1007/s11481-018-9816-3

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  56 in total

1.  Analyzing real-time PCR data by the comparative C(T) method.

Authors:  Thomas D Schmittgen; Kenneth J Livak
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

2.  Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain.

Authors:  Iain P Chessell; Jonathan P Hatcher; Chas Bountra; Anton D Michel; Jane P Hughes; Paula Green; Julie Egerton; Melanie Murfin; Jill Richardson; Wendy L Peck; Caroline B A Grahames; Maria Anna Casula; Yiangos Yiangou; Rolfe Birch; Praveen Anand; Gary N Buell
Journal:  Pain       Date:  2005-04       Impact factor: 6.961

Review 3.  P2X receptors as cell-surface ATP sensors in health and disease.

Authors:  Baljit S Khakh; R Alan North
Journal:  Nature       Date:  2006-08-03       Impact factor: 49.962

4.  P2X7-like receptor activation in astrocytes increases chemokine monocyte chemoattractant protein-1 expression via mitogen-activated protein kinase.

Authors:  W Panenka; H Jijon; L M Herx; J N Armstrong; D Feighan; T Wei; V W Yong; R M Ransohoff; B A MacVicar
Journal:  J Neurosci       Date:  2001-09-15       Impact factor: 6.167

5.  Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus.

Authors:  James G McLarnon; Jae K Ryu; Douglas G Walker; Hyun B Choi
Journal:  J Neuropathol Exp Neurol       Date:  2006-11       Impact factor: 3.685

Review 6.  The P2X7 receptor: a key player in IL-1 processing and release.

Authors:  Davide Ferrari; Cinzia Pizzirani; Elena Adinolfi; Roberto M Lemoli; Antonio Curti; Marco Idzko; Elisabeth Panther; Francesco Di Virgilio
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

7.  P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis.

Authors:  Carlos Matute; Iratxe Torre; Fernando Pérez-Cerdá; Alberto Pérez-Samartín; Elena Alberdi; Estibaliz Etxebarria; Amaia M Arranz; Rivka Ravid; Alfredo Rodríguez-Antigüedad; MaríaVictoria Sánchez-Gómez; María Domercq
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

8.  Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia.

Authors:  Tomohisa Suzuki; Izumi Hide; Katsutoshi Ido; Shinichi Kohsaka; Kazuhide Inoue; Yoshihiro Nakata
Journal:  J Neurosci       Date:  2004-01-07       Impact factor: 6.167

9.  Increased MCP-1 and microglia in various regions of the human alcoholic brain.

Authors:  Jun He; Fulton T Crews
Journal:  Exp Neurol       Date:  2007-12-03       Impact factor: 5.330

Review 10.  Neuropharmacology of alcohol addiction.

Authors:  V Vengeliene; A Bilbao; A Molander; R Spanagel
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

View more
  9 in total

Review 1.  Metabolic regulation of inflammasomes in inflammation.

Authors:  Qiuli Yang; Ruichen Liu; Qing Yu; Yujing Bi; Guangwei Liu
Journal:  Immunology       Date:  2019-04-08       Impact factor: 7.397

2.  Role of MyD88 in IL-1β and Ethanol Modulation of GABAergic Transmission in the Central Amygdala.

Authors:  Michal Bajo; Reesha R Patel; David M Hedges; Florence P Varodayan; Roman Vlkolinsky; Tony D Davis; Michael D Burkart; Yuri A Blednov; Marisa Roberto
Journal:  Brain Sci       Date:  2019-12-07

Review 3.  Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome.

Authors:  Júlia Leão Batista Simões; Margarete Dulce Bagatini
Journal:  J Neuroimmune Pharmacol       Date:  2021-01-18       Impact factor: 4.147

Review 4.  The Purinergic P2X7 Receptor-NLRP3 Inflammasome Pathway: A New Target in Alcoholic Liver Disease?

Authors:  Brendan Le Daré; Pierre-Jean Ferron; Thomas Gicquel
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

5.  High levels of extracellular ATP lead to different inflammatory responses in COVID-19 patients according to the severity.

Authors:  Gilnei Bruno da Silva; Daiane Manica; Alana Patrícia da Silva; Greicy Cristine Kosvoski; Marceli Hanauer; Charles Elias Assmann; Júlia Leão Batista Simões; Micheli Mainardi Pillat; Jéssica Dotto de Lara; Filomena Marafon; Amanda Gollo Bertollo; Maiqueli E D Mingoti; Jullye Gavioli; Gislaine Zilli Réus; Gabriela Gonçalves de Oliveira; Zuleide Maria Ignácio; Margarete Dulce Bagatini
Journal:  J Mol Med (Berl)       Date:  2022-03-06       Impact factor: 4.599

Review 6.  Pathophysiological Role of Purinergic P2X Receptors in Digestive System Diseases.

Authors:  Qimin An; Gengyu Yue; Xiaoxu Yang; Jun Lou; Weixi Shan; Jianhong Ding; Zhe Jin; Yanxia Hu; Qian Du; Qiushi Liao; Rui Xie; Jingyu Xu
Journal:  Front Physiol       Date:  2021-12-24       Impact factor: 4.566

7.  Blocking of P2X7r Reduces Mitochondrial Stress Induced by Alcohol and Electronic Cigarette Exposure in Brain Microvascular Endothelial Cells.

Authors:  Naveen Mekala; Nishi Gheewala; Slava Rom; Uma Sriram; Yuri Persidsky
Journal:  Antioxidants (Basel)       Date:  2022-07-06

8.  Pairing Binge Drinking and a High-Fat Diet in Adolescence Modulates the Inflammatory Effects of Subsequent Alcohol Consumption in Mice.

Authors:  Macarena González-Portilla; Sandra Montagud-Romero; Francisco Navarrete; Ani Gasparyan; Jorge Manzanares; José Miñarro; Marta Rodríguez-Arias
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

Review 9.  P2X7R antagonists in chronic stress-based depression models: a review.

Authors:  Iven-Alex von Muecke-Heim; Clemens Ries; Lidia Urbina; Jan M Deussing
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-07-19       Impact factor: 5.270

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.